|
US5457208A
(en)
|
1993-06-21 |
1995-10-10 |
Regents Of The University Of Minnesota |
Kappa opioid receptor antagonists
|
|
WO2000069858A1
(en)
|
1999-05-12 |
2000-11-23 |
F. Hoffmann-La Roche Ag |
Imidazodiazepine derivative
|
|
JP2004510789A
(ja)
|
2000-10-05 |
2004-04-08 |
モーラー，ハンス |
選択的抗不安治療薬
|
|
JP2004518654A
(ja)
|
2000-12-21 |
2004-06-24 |
ザ マクレーン ホスピタル コーポレーション |
鬱病の治療法
|
|
US6974824B2
(en)
|
2001-01-08 |
2005-12-13 |
Research Triangle Institute |
Kappa opioid receptor ligands
|
|
DE60319812T2
(de)
|
2002-03-28 |
2009-04-23 |
Wisys Technology Foundation, Inc., Madison |
Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
|
|
KR101025633B1
(ko)
|
2002-09-19 |
2011-03-30 |
일라이 릴리 앤드 캄파니 |
오피오이드 수용체 안타고니스트로서의 디아릴 에테르
|
|
US7396943B2
(en)
|
2003-03-07 |
2008-07-08 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
CN1756746A
(zh)
|
2003-03-07 |
2006-04-05 |
伊莱利利公司 |
作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物
|
|
BRPI0417156A
(pt)
|
2003-12-12 |
2007-03-06 |
Lilly Co Eli |
composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
|
|
CN1894240A
(zh)
|
2003-12-22 |
2007-01-10 |
伊莱利利公司 |
阿片受体拮抗剂
|
|
EP1730140B1
(en)
|
2004-03-12 |
2008-06-25 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
EP1727788B1
(en)
|
2004-03-12 |
2010-07-28 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
AU2005222640A1
(en)
|
2004-03-12 |
2005-09-29 |
The Mclean Hospital Corporation |
Salvinorin derivatives and uses thereof
|
|
CA2557794A1
(en)
|
2004-03-15 |
2005-10-06 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
JP2007529523A
(ja)
|
2004-03-15 |
2007-10-25 |
イーライ リリー アンド カンパニー |
肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物
|
|
US8551986B2
(en)
|
2005-12-08 |
2013-10-08 |
The Mclean Hospital Corporation |
Treatment of sequelae of psychiatric disorders
|
|
DK2001456T3
(da)
|
2006-04-04 |
2010-04-12 |
Emodys Gmbh |
Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
|
|
US20100222345A1
(en)
|
2006-08-09 |
2010-09-02 |
Caroline Jean Diaz |
Novel compounds as antagonists or inverse agonists for opioid receptors
|
|
WO2008021849A2
(en)
|
2006-08-09 |
2008-02-21 |
Smithkline Beecham Corporation |
Novel compounds as antagonists or inverse agonists at opioid receptors
|
|
CN101511808A
(zh)
|
2006-09-08 |
2009-08-19 |
辉瑞产品公司 |
二芳基醚衍生物及其用途
|
|
WO2009094260A1
(en)
|
2008-01-22 |
2009-07-30 |
Eli Lilly And Company |
Kappa selective opioid receptor antagonist
|
|
BR112013002846A2
(pt)
|
2010-08-05 |
2016-06-07 |
Conrig Pharma Aps |
derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
|
|
EP2773352B1
(en)
|
2011-12-09 |
2017-06-28 |
Research Triangle Institute |
1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
|
|
MX368870B
(es)
|
2013-12-20 |
2019-10-21 |
H Lundbeck As |
Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.
|
|
US10377698B2
(en)
|
2015-03-30 |
2019-08-13 |
University Of Innsbruck |
Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production
|
|
US10709685B2
(en)
|
2015-05-28 |
2020-07-14 |
Georgetown University |
Use of methadone metabolites for treatment of anxiety and depression
|
|
WO2017218518A1
(en)
|
2016-06-13 |
2017-12-21 |
Board Of Regents Of The University Of Texas System |
Pharmaceutical compositions and methods for treatment of pain
|
|
EP3490542A4
(en)
|
2016-07-26 |
2020-07-08 |
Flagship Pioneering Innovations V, Inc. |
NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
|
|
JP7048572B6
(ja)
|
2016-09-16 |
2023-12-20 |
リサーチ トライアングル インスティテュート |
テトラヒドロイソキノリンカッパーオピオイドアンタゴニスト
|
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
|
ES2926533T3
(es)
|
2017-03-17 |
2022-10-26 |
Scripps Research Inst |
Antagonistas del receptor opioideo kappa y productos y métodos relacionados con los mismos
|
|
PH12018000077B1
(en)
|
2017-07-05 |
2021-07-09 |
Frimline Private Ltd |
A pharmaceutical composition for neuropathic pain
|
|
US20190255036A1
(en)
|
2018-02-16 |
2019-08-22 |
Alexander Kariman |
Compound and method for reducing neuropathic pain and depression
|
|
WO2019183556A1
(en)
|
2018-03-23 |
2019-09-26 |
University Of Kansas |
Cyclic tetrapeptide analogs
|
|
US11491144B2
(en)
|
2018-03-30 |
2022-11-08 |
The Florida State University Research Foundation, Incorporated |
Methods of treating fragile X mental retardation syndrome
|
|
JP2022505676A
(ja)
|
2018-10-23 |
2022-01-14 |
ブラックソーン セラピューティクス インコーポレイテッド |
患者のスクリーニング、診断、及び層別化のためのシステム及び方法
|
|
US20200171025A1
(en)
|
2018-11-29 |
2020-06-04 |
Srinivasa Rao Parella |
Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
|
|
US11266627B1
(en)
*
|
2021-05-04 |
2022-03-08 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for the treatment of depression
|
|
CN114195693A
(zh)
*
|
2020-09-17 |
2022-03-18 |
广东东阳光药业有限公司 |
一种酰胺化合物的晶型及其制备方法
|
|
US12161622B2
(en)
|
2021-05-04 |
2024-12-10 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for the treatment of depression
|
|
AU2022268720A1
(en)
|
2021-05-04 |
2023-12-21 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for the treatment of depression
|
|
EP4489730B1
(en)
|
2022-03-07 |
2026-01-21 |
Janssen Pharmaceuticals, Inc. |
Compositions comprising aticaprant
|
|
WO2023170547A1
(en)
|
2022-03-07 |
2023-09-14 |
Janssen Pharmaceuticals, Inc. |
Pure forms of crystalline aticaprant
|